Arix Bioscience PLC has announced that its Chief Executive Officer, Robert Lyne, will be stepping down from his position to pursue a new opportunity and will leave the company by the end of 2023. Peregrine Moncreiffe, Chairman of Arix, expressed gratitude for Lyne's contributions to the company and stated that the board's primary focus going forward will be to maximize shareholder returns and unlock the value in the Arix portfolio. The board will determine appropriate board and management arrangements following the outcome of a strategic review. Arix Bioscience is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies.